Article
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
Blood advances - 22 Oct 2024
Hoff Fieke W, Blum William G, Huang Ying, Welkie Rina Li, Swords Ronan T, Traer Elie, Stein Eytan M, Lin Tara L, Archer Kellie J, Patel Prapti A, Collins Robert H, Baer Maria R, Duong Vu H, Arellano Martha L, Stock Wendy, Odenike Olatoyosi, Redner Robert L, Kovacsovics Tibor, Deininger Michael W, Zeidner Joshua F, Olin Rebecca L, Smith Catherine C, Foran James M, Schiller Gary J, Curran Emily K, Koenig Kristin L, Heerema Nyla A, Chen Timothy, Martycz Molly, Stefanos Mona, Marcus Sonja G, Rosenberg Leonard, Druker Brian J, Levine Ross L, Burd Amy, Yocum Ashley O, Borate Uma M, Mims Alice S, Byrd John C, Madanat Yazan F
Abstract excerpt
ABSTRACT: Although the 2022 European LeukemiaNet (ELN) acute myeloid leukemia (AML) risk classification reliably predicts outcomes in younger patients treated with intensive chemotherapy, it is unclear whether it applies to adults ≥60 years treated with lower-intensity treatment (LIT). We aimed to test the prognostic impact of ELN risk in patients with newly diagnosed (ND) AML aged ≥60 years given LIT and to...
Topics
Join the communities discussing this publication.